Patrick Mills, MD
Urology · Homewood, ALNPI 1700844263
Payments from drug & device makers
Across 161 payments — averaging $19.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sumitomo Pharma America, Inc.$537
- Antares Pharma, Inc.$517
- AbbVie$194
- Urovant Sciences Inc$191
- Pfizer$183
- Progenics Pharmaceuticals, Inc.$140
- plus $1K from 35 others
What the payments were for
- Food & beverage$3,00495%
- Education$1735%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sumitomo Pharma America, Inc. | 31 | $537 |
| Antares Pharma, Inc. | 29 | $517 |
| AbbVie(2 entities) | 6 | $194 |
| Urovant Sciences Inc | 10 | $191 |
| Pfizer | 9 | $183 |
| Progenics Pharmaceuticals, Inc. | 7 | $140 |
| Urogen Pharma, Inc. | 7 | $133 |
| Coloplast | 5 | $109 |
| Procept Biorobotics Corporation | 3 | $94 |
| Bayer | 4 | $77 |
| Immunitybio, Inc. | 2 | $74 |
| Olympus America Inc. | 2 | $59 |
| Johnson & Johnson | 3 | $58 |
| Verity Pharmaceuticals Inc. | 3 | $57 |
| Neotract Inc. | 1 | $56 |
| Astellas Pharma US Inc | 3 | $52 |
| Merck | 2 | $49 |
| Halozyme Inc | 2 | $45 |
| Tolmar Pharmaceuticals, Inc. | 2 | $43 |
| Myovant Sciences Inc. | 3 | $41 |
| AstraZeneca | 1 | $35 |
| Cook Medical LLC | 2 | $34 |
| Medtronic | 2 | $32 |
| Mission Pharmacal Company | 2 | $31 |
| 180 Medical, Inc. | 1 | $30 |
| Dendreon Pharmaceuticals LLC | 1 | $27 |
| Axonics, Inc. | 2 | $26 |
| Endo USA, Inc. | 1 | $25 |
| Rochester Medical Corporation | 1 | $23 |
| Myriad Genetic Laboratories, Inc. | 1 | $22 |
| Tolmar, Inc. | 1 | $21 |
| Pharmaand GmbH | 1 | $21 |
| Convatec Inc. | 1 | $21 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $20 |
| Endo Pharmaceuticals Inc. | 1 | $19 |
| Hollister Incorporated | 1 | $17 |
| Boston Scientific | 1 | $15 |
| Bard Access Systems, Inc. | 1 | $14 |
| Therapeuticsmd, Inc. | 1 | $13 |
| Photocure Inc | 1 | $13 |
| Travere Therapeutics, Inc. | 3 | $10 |
How this compares
$3,177 in reported general payments places this provider in the 40th percentile of 179 urology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 85 | $64,883 |
| MyrbetriqMirabegron | 63 | $46,558 |
| Testosterone | 94 | $22,644 |
| XyostedTestosterone Enanthate | 21 | $17,148 |
| ElmironPentosan Polysulfate Sodium | 11 | $11,346 |
| Tamsulosin Hcl | 409 | $6,560 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 181 | $5,501 |
| Testosterone Cypionate | 170 | $4,536 |
| Cefdinir | 264 | $3,826 |
| Potassium Citrate ErPotassium Citrate | 28 | $3,816 |
| Finasteride | 179 | $2,747 |
| Dutasteride | 29 | $1,633 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 59 | $1,397 |
| NitrofurantoinNitrofurantoin Macrocrystal | 30 | $1,095 |
| Oxybutynin Chloride ErOxybutynin Chloride | 26 | $966 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $537 | $64,88385 claims |
| Astellas Pharma US IncMyrbetriq | $52 | $46,55863 claims |
| Antares Pharma, Inc.Xyosted | $517 | $17,14821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 179 urology providers in Alabama.
Other urology in Homewood
- Vincent BivinsHomewood$1.3M
- Charles BuggHomewood$544K
- Brian ChristineHomewood$372K
- Austin LutzHomewood$367K
- Mark DeguentherHomewood$342K
- Paula RookisHomewood$174K
- Bryant PooleHomewood$123K
- Andrew StrangHomewood$91K
- Michael BrewerHomewood$77K
- Rachel EngelbergHomewood$61K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.